Physician profile
Mark J Pascuzzi
NPI 1033164207
$1,427.88
in general payments reported to CMS, 2019-2025
25 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $132 · 2021: $99.98 · 2022: $183 · 2023: $192 · 2024: $229 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.14 | 2019-2024 | |
| Astellas Pharma US INC | $146.65 | 2019-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $132.14 | 2019-2023 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $115.61 | 2019-2025 | |
| Gynesonics, INC. | $80.05 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Axsome Therapeutics, INC. | $69.80 | 2024-2025 | Auvelity |
| Sage Therapeutics, LLC | $64.16 | 2020-2025 | Zurzuvae |
| Pfizer INC. | $58.37 | 2023-2025 | |
| Myovant Sciences INC. | $54.19 | 2021-2022 | |
| Lupin INC. | $52.26 | 2019 | |
| Amag Pharmaceuticals, INC. | $38.06 | 2019 | |
| Sumitomo Pharma America, INC. | $37.04 | 2024-2025 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $32.57 | 2019-2020 | |
| Duchesnay USA Incorporated | $30.79 | 2019 | |
| Becton, Dickinson and Company | $22.31 | 2023 | Bd Surepath Collection Vial |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $20.35 | 2019 | |
| Mayne Pharma Commercial LLC | $17.98 | 2023 | |
| Shield Therapeutics INC | $17.42 | 2024 | |
| Agile Therapeutics, INC. | $17.30 | 2022 | |
| Evofem Biosciences, INC. | $15.12 | 2021 | |
| Davol INC. | $14.95 | 2022 | |
| Millicent US INC | $14.42 | 2025 | Femlyv |
| Minerva Surgical, INC | $12.87 | 2023 | |
| Merck Sharp & Dohme LLC | $11.19 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pascuzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.